logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Farmaindustria highlights the consolidation of Spain’s leadership in biomedical R&D, within the Strategic Plan of the Pharmaceutical Industry

In the framework of its General Assembly, held in Madrid

Asamblea General Farmaindustria

Source: www.actasanitaria.com

In the framework of its General Assembly, held in Madrid, Farmaindustria has highlighted, this Thursday, 23 June, access to innovation, strengthening production and consolidating Spain’s leadership in biomedical R&D as the basis for the Strategic Plan for the Pharmaceutical Industry.

“We should be proud to be part of a sector that, more than ever, has been part of the solution to this terrible pandemic,” said Juan López-Belmonte, president of the Spanish pharmaceutical industry employers’ association. He also emphasised the potential and commitment of the sector to contribute to the economic and social reactivation of Spain, and encouraged members “to persevere in the great work carried out during the two years of the health crisis”.

Lopez Belmonte Asamblea

“It has been shown that the country’s well-being and economy depend to a large extent on health, and health depends on medicines and the research that makes them possible. The whole population has seen our commitment, our responsiveness, our usefulness. We are no longer something distant, that people remember only when they fall seriously ill,” said Juan López-Belmonte.

This response to the pandemic also shows, according to the head of Farmaindustria, that this sector “is critical for Spain not only from the point of view of health care, but also from the economic and social perspective”, and that the pharmaceutical industry has the strengths and the capacity “to be one of the strategic sectors that contribute to the economic and social reactivation of Spain and to reinforce the productive model of the near future”.

To emerge from the crisis

Spain needs strategic sectors on which to rely to emerge from the crisis and build its future, “and we have objective data that endorse us as one of those sectors that the country needs, as shown by our contribution to investment in R&D, where we are the leading industrial sector in the country along with the automotive industry, or our level of exports, which has set record figures in recent years and has placed the medicine as the fourth most exported product in Spain,” continued López-Belmonte.

In the opinion of the head of this employers’ association, with these strengths and a medium- to long-term vision, it will be possible to “develop the potential” of this sector. Farmaindustria considers that the Strategic Plan for the Pharmaceutical Industry that the Government announced in its Recovery, Transformation and Resilience Plan is the appropriate framework for doing so.

Access on par with the EU

This strategy – which has already begun to be addressed in a first meeting with the Ministry of Health – should be based on three main pillars, summarised the president of the employers’ association, such as “reconciling better patient access to innovation with the sustainability of the health system, strengthening the productive fabric and making Spain an international benchmark in biomedical research, based on the leadership already gained in clinical trials of medicines”.

With regard to access, the president of Farmaindustria pointed out that the figures are worrying and far removed from those of the benchmark countries in the European Union (EU). “Spain should have a level of access equal to that of the European reference countries. In the same way that we have been vaccinated against Covid-19 at the same time as the Germans or the French, we should have access to the same medicines as them,” he said, and reiterated the commitment of pharmaceutical companies to apply solutions within a framework of financial sustainability of the health system.

Farmaindustria’s General Assembly was the first for the organisation’s new director general, Juan Yermo, who took office on 3 May. Yermo reviewed the activity of the last year and presented to the associates the lines of work for 2022.

Juan Yermo Asamblea

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.